Celsion Corporation has done a 61.8 percent Fibonacci retracement after exploding 180 percent higher last week after releasing data from its Ovation Study.
The Ovation Study is a Phase Ib dose escalating clinical trial combining GEN-1, the company’s DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.
Of the 14 patients treated in the study, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate (“DCR”) and an 86% objective response rate (“ORR”). Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses.
Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Seven out of eight (87%) patients in the highest two dose cohorts experienced a R0 surgical resection. All five patients treated at the highest dose cohort experienced a R0 surgical resection.
All patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells.
Of the eight patients who have received GEN-1 treatment over one year ago (cohort 1 – 3) and are being followed; only two patients’ cancer has progressed. This compares favorably to the historical median progression free survival (PFS) of 12 months for newly-diagnosed patients with Stage III and IV ovarian cancer that undergo neoadjuvant chemotherapy followed by interval debulking surgery. Of the remaining six patients who have been on the study for over one year, their average PFS as of September 30, 2017 is 18 months with the longest progression-free patient at 24 months.
Celsion Corporation said, “The intraperitoneal treatment of GEN-1 in conjunction with neoadjuvant chemotherapy resulted in dose dependent increases in IL-12 and Interferon-gamma (IFN-g) levels that were predominantly in the peritoneal fluid compartment with little to no changes observed in the patients’ systemic circulation. These and other post-treatment changes including decreases in VEGF levels in peritoneal fluid are consistent with an IL-12 based immune mechanism. These translational research findings demonstrate that GEN-1 in ovarian cancer patients is biologically active and creates a shift in the primary tumor and in the surrounding tumor environment in the peritoneal cavity that promotes a pro-immune T-cell population dynamic and conversion of tumor naive T-cell into cytotoxic effector T-cells in the tumor microenvironment.”
The data from the first 14 patients who have completed treatment in the Ovation Study was highly encouraging. GEN-1 plus standard chemotherapy produced positive clinical results, with no dose limiting toxicities and promising dose dependent efficacy signals which correlate well with successful surgical outcomes.
You can find out more about Celsion on their website here.
Celsion Corporation Maxim Group Upgrade
After the Ovation Study data was released, analysts at Maxim Group upgraded Celsion Corporation stock from a Hold to a Buy rating. A Buy rating is Maxim Group’s highest rating. Maxim Group has a $7.00 price target on the stock which is 109.6% upside from the previous close of $3.34.
Celsion Corporation Stock Chart
Celsion is nearing its 61.8 percent retracement level at $3.23. The large players volume has hardly retraced which suggests large players are accumulating Celsion on this most recent pullback. The positive Twiggs Money Flow confirms the stock is under accumulation.
Celsion stock does not offer a high quality setup at the moment. Price movement has been a little bit too volatile to find a good entry and exit point. It is probably a good idea to wait for a consolidation first.
Celsion Corporation Stock
The Piotroski-F score of Celsion (CLSN) is 4. This is a neutral score and indicates average health and profitability for CLSN. The profitability ratios for CLSN are negative, so there is not much use analyzing them. CLSN has a Return On Assets of -73.70%. This is below the industry average of -41.76%. CLSN's Profit Margin of -4371.26% is worse than the rest of the industry. The industry average Profit Margin is -247.89%. 85% of the industry peers have a better Profit Margin.
When comparing the current price to the book value of CLSN, we can conclude it is valued correctly. It is trading at 4.21 times its book value. Compared to an average industry price book ratio of 4.19, CLSN is priced inline with its industry peers. The Price/Earnings Ratio is negative for CLSN. In the last year negative earnings were reported. Besides the negative Price/Earnings Ratio, the Forward Price/Earnings Ratio is negative for CLSN. No positive earnings are expected for the next year.
The Earnings Per Share has grown by an impressive 28.55% over the past year. CLSN is expected to show a strong growth in Earnings Per Share. In the coming 2 years, the EPS will grow by 68.44% yearly. The EPS growth is accelerating: in the next 2 years the growth will be better than in the last years.
CLSN has a Piotroski-F score of 4. This indicates an average health and profitability for CLSN. CLSN has a Current Ratio of 0.54. This is a bad value and indicates that CLSN is not financially healthy enough and could expect problems in meeting its short term obligations. Compared to an average industry Current Ratio of 4.63, CLSN is worse placed to pay its short term obligations than its industry peers. 99% of its industry peers have a better Current Ratio. A Quick Ratio of 0.54 indicates that CLSN may have some problems paying its short term obligations. When comparing the Quick Ratio of CLSN to the average industry Current Ratio of 4.45, CLSN is less able to pay its short term obligations than its industry peers. 99% of its industry peers have a better Quick Ratio. Compared to an average industry Debt to Equity Ratio of 0.00, CLSN is a more dependent on financing than its industry peers. Based on the Altman-Z score of -13.73, CLSN is in the distress zone and has some risk of bankruptcy. Compared to an average industry Altman-Z score of 1.84, CLSN is in worse financial state than most of its industry peers. 91% of its industry peers have a better Altman-Z score.
Latest posts by Lance Jepsen
- Lam Research Stock Higher On Needham & Company Price Hike - October 19, 2017
- Taiwan Semiconductor Beats On Earnings and Revenue - October 19, 2017
- KeyCorp Stock Bullish Flag Flush On Analyst Buy Rating - October 19, 2017